Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis

Pelzer, U; Blanc, JF; Melisi, D; Cubillo, A; Von Hoff, DD; Wang-Gillam, A; Chen, LT; Siveke, JT; Wan, Y; Solem, CT; Botteman, MF; Yang, YJ; de Jong, FA; Hubner, RA

Pelzer, U (reprint author), Charite Univ Med Berlin, Dept Hematol Oncol Tumorimmunol, Augustenburger Pl 1, D-13353 Berlin, Germany.

BRITISH JOURNAL OF CANCER, 2017; 116 (10): 1247

Abstract

Background: In the NAPOLI-1 Phase 3 trial, nal-IRI + 5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 vs 4.......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索